News and Trends 28 Oct 2022 Cali Biosciences publishes ropivacaine results Cali Biosciences Co., Ltd. has announced two milestones for CPL-01, its long-acting ropivacaine for post-operative analgesia and opioid elimination/reduction. The company saw the publication of CPL-01, an Investigational Long-Acting Ropivacaine, Exhibits Extended-Release Properties after Mini-abdominoplasty in the Japan Journal of Medicine. It also gave a presentation of preclinical data at the American Association of Pharmaceutical […] October 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 Singapore approves gas fermentation-powered protein A food ingredient developed by the Finnish startup Solar Foods has earned its first market approval in Singapore. The product is brewed using microorganisms fed with carbon dioxide and electricity — a more sustainable alternative to conventional animal protein. Increasing numbers of fermentation-derived food products are reaching the market, including ingredients developed by Motif FoodWorks, […] October 26, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 26 Oct 2022 Study shows ability to develop and apply targeted treatment in head and neck cancers A joint study looked at the development identification of specific markers to improve risk assessment of patients with difficult to treat head and neck tumors. Malignant tumors in these areas are very heterogeneous and have a lack of prognostic markers – a significant impediment to personalized treatment. The joint study by MedUni Vienna and the […] October 26, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 First patient dosed in trial to assess predictive performance of immuno-oncology therapy The first patient has been dosed at the Macquarie University Hospital in Sydney as part of a clinical trial to evaluate whether a drug can predict patient response to immuno-oncology therapy targeting a number of solid tumor types. ImaginAb Inc. is a biotech company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and next generation […] October 26, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 Partnership between Paradigm4 and Alnylam accelerates drug target discovery New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam. Paradigm4’s REVEAL integrative analytics platform enables extraordinary pace and productivity Alnylam Pharmaceuticals to access the targets for its therapeutics pipeline at a very fast pace. Using the cloud-based scientific analytics […] October 26, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 26 Oct 2022 Neuraxpharm to commercialize device giving early warning of epileptic seizures A wearable medical device that can give an early warning of an epileptic seizure has been developed by medical device startup, mjn-neuro. Central nervous system (CNS) specialist Neuraxpharm Group entered the digital health market by signing a commercialization agreement with the developer for mjn-SERAS with exclusivity in Europe. With this agreement, Neuraxpharm increases its end-to-end […] October 26, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 Forsea Foods raises $5.2M in bid to redress destruction of marine life With eels becoming an endangered species and demand for its meat continuing to increase, the Israeli food-tech startup Forsea Foods has raised $5.2 million in a seed round to address the issue. Forsea Foods Ltd. is the first company to use organoid technology for culturing seafood products. Its aim is to redress the destruction of […] October 26, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 Partnership for better understanding of Sjögren’s syndrome announced by Evotec A molecular patient database for Sjögren’s syndrome (SjS) and systemic lupus erythematosus (SLE) is to be generated following a partnership between Evotec SE and a German university. Evotec made the announcement yesterday (Tuesday) that it will work with Hannover Medical School (MHH). The strategic partnership between Evotec and MHH aims at achieving a better understanding […] October 26, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 Scancell signs agreement with Genmab Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer and infectious disease, has signed a licensing agreement with Genmab, an international biotechnology company, to develop and commercialize a Scancell investigational anti-glycan monoclonal antibody into novel therapeutic products. Genmab has been granted the exclusive right to develop and commercialize the Scancell antibody […] October 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 New UK spinout VacV Biotherapeutics emerges from stealth to work on cancer immunotherapies VacV Biotherapeutics, a cancer immunotherapy company developing innovative viral-based therapies, emerged from stealth mode today to advance its pipeline of pre-clinical assets with best-in-class potential, towards the clinic. VacV Biotherapeutics has spun out of Barts Cancer Institute and Queen Mary University of London following 20 years of research by immunotherapy experts Yaohe Wang, Nicholas Lemoine, […] October 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 Inotrem study for the treatment of critically ill COVID-19 patients meets endpoints Inotrem has announced positive results for ESSENTIAL, its phase II clinical trial in COVID-19 patients hospitalized in critical care units and experiencing acute respiratory distress. The French clinical stage biotech company specializes in immunotherapies for acute and chronic inflammatory syndromes. The announcement was made at the European Society of Intensive Care Medicine’s Annual Congress, held […] October 26, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 Recursion announces $150M private placement U.S. biotech Recursion Pharmaceuticals has entered into a stock purchase agreement for the sale of an aggregate of approximately 15.3 million shares of its Class A common stock in a private placement. It was led by Kinnevik AB, with participation by Baillie Gifford, Mubadala Investment Company, Laurion Capital Management, Invus, and Platinum Asset Management. The […] October 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email